|
Media:
|
Maureen Byrne
GCI Group
212-886-3312
|
|
Investors:
|
Therese Crozier
Corporate Communications
510 789-4331
|
[/TABLE]
For Immediate Release
SANGSTAT BOARD ELECTS JEAN-JACQUES BIENAIMÉ AS
CHAIRMAN
Fremont, California - October 16, 2000 - SangStat, The
Transplant Companyâ (Nasdaq: SANG)
today announced the SangStat Board of Directors has elected Jean-Jacques
Bienaimé, the Company's current President and CEO, as Chairman.
"I am looking forward to building on the foundation and focus
on transplantation that has characterized SangStat during its first phase of
development," said Jean-Jacques Bienaimé, President, CEO and Chairman.
"As we look to the future we will concentrate on building the business by
capitalizing on our strengths in the development, sales and marketing of high
value therapeutics."
Mr. Bienaimé, CEO of SangStat since February 1999,
replaces Dr. Philippe Pouletty as Chairman. Dr. Pouletty has resigned from
SangStat's Board of Directors in order to focus on DrugAbuse Sciences, a
biotechnology company dedicated to novel therapies to treat alcohol abuse and
drug addictions which he founded in 1994 and of which he is Chairman and
president. Founder of SangStat, Dr. Pouletty has provided leadership to the
company as CEO and as a director from 1988 to February 1999, and as Chairman of
the Board of Directors since 1995.
Before joining SangStat as President and COO in 1998 and then
CEO in 1999, Jean- Jacques Bienaimé was Senior Vice-President of
Corporate Marketing and Business Development at Rhône Poulenc Rorer Inc.
(RPR), now Aventis. Since 1992 he held various positions of increasing
responsibility within RPR's US and International marketing, sales and corporate
strategy department, including full P&L responsibility for a 650 person US
organization with revenues of over $400 million. Previously at Genentech, Mr.
Bienaimé was responsible for launching Activase®, one of
the most successful biotechnology drug launches in the United States. Mr.
Bienaimé received his Masters of Business Administration from the Wharton
School at the University of Pennsylvania and a degree in Economics from Ecole
Supérieure de Commerce de Paris in France. He is a member of the board of
directors of Aerogen Inc. and of Fox Chase Cancer Center in Philadelphia.
SangStat, The Transplant Company®
SangStat, The Transplant Companyâ , is a global bio-pharmaceutical company
applying a disease management approach to improving the outcome of organ, bone
marrow, and stem cell transplantation. Since 1988, SangStat has built a family
of products and services to address the pre-transplant, acute care and chronic
phases of transplant in the worldwide market. SangStat's The Transplant
Pharmacyâ is a dedicated mail order
pharmacy that provides direct drug distribution and patient-focused management
services. TransplantRx.com was introduced in 1999 as an on-line component and
one-stop- shop providing e-commerce, content, and community for transplant
recipients and providers. The company's long-term goal is to expand this success
in transplantation to the broader immunosuppressive market.
This press release contains forward-looking statements
that involve risks and uncertainties, including statements regarding the
company's (1) strengths in the development, marketing, and sales of products,
(2) commitments, intents and goals, and (3) product development and potential
future sales. Forward-looking statements reflect SangStat's current views with
respect to future events. Actual results may vary materially and adversely from
those anticipated, believed, estimated, or otherwise indicated. There can be no
assurance that any product candidate under development will be safe, effective,
receive regulatory approval or, if approved, will be capable of being
manufactured in commercial quantities at an economical cost, will not infringe
the proprietary rights of others or will achieve market acceptance. For a
discussion of these and other factors that might result in different outcomes,
see "Risk Factors" in SangStat's 1999 Annual Report on Form 10-K, its 2000
quarterly reports on Form 10-Qs and other documents (including registration
statements on Form S-3) filed with the Securities and Exchange Commission.
# # #
SangStat will hold a conference call at 4:30pm Eastern
Time on Monday, October 16, 2000. To access the call dial 888-323-5255; the call
leader is Jean-Jacques Bienaimé; confirmation number is 9588414. A replay
will be available until Wednesday, October 18 at 4:30pm EST (800-385-2540). You
can find full copies of our latest press releases on the web at
www.sangstat.com.
[/HTML]
© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission
